In Lisbon, ESC Preventive Cardiology 2025 brings together experts dedicated to enhancing preventive measures in cardiology. Attendees will gain insights into evidence-based approaches, community health strategies, and innovative technologies improving patient outcomes. Our team will present research addressing key challenges in prevention and discuss collaboration opportunities to drive impactful solutions. Let’s meet to explore shared goals in advancing preventive care.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
